At GLP-1 Newsroom, we dont recommend compounded GLP-1s
BrightMeds has not received an FDA warning letter as of April 2026
Robert Goldman MD, DO, PhD, FAASP Worldhealth.net A new phase 3 trial published in The Lancet reveals that #retatrutide, a nextgeneration GLP3 #agonist, may outperform todays GLP1 drugs in both #diabetes control and weight loss
The Medicines and Healthcare products Regulatory Agency said anyone experiencing side effects should talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme.
About the authorView full bio Michael Stewart, MRPharmS Medicine Leaflet Review Manager Contractor, Pharmacist BPharm (Hons), MRPharmS Michael is a community pharmacist practicing in the Midlands and South Yorkshire with more than 20 years experience advising on medicines and medical conditions
Our confidential and affordable services are designed to support you every step of the way on your path to better health